Cronos Group (CRON) Stock Price, News & Analysis

+0.11 (+4.66%)
(As of 04/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
2.33 million shs
Average Volume
4.22 million shs
Market Capitalization
$943.56 million
P/E Ratio
Dividend Yield
Price Target

Cronos Group MarketRank™ Stock Analysis

Analyst Rating
2.33 Rating Score
14.7% Upside
$2.83 Price Target
Short Interest
2.79% of Float Sold Short
Dividend Strength
News Sentiment
0.67mentions of Cronos Group in the last 14 days
Based on 3 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.01) to $0.03 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.74 out of 5 stars

Medical Sector

596th out of 909 stocks

Medicinals & Botanicals Industry

3rd out of 10 stocks

CRON stock logo

About Cronos Group Stock (NASDAQ:CRON)

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

CRON Stock Price History

CRON Stock News Headlines

Cannabis: One Stock to Play the Movement (CRON)
With talk of decriminalizing marijuana once again becoming part of the national conversation, there's one cannabis ETF that may provide the best value
Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars
Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.
3 Cannabis Penny Stocks to Buy for 3-Bagger Returns
Why Marijuana Stocks Got Burnt Today
Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars
Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.
The 3 Best Meme Stocks to Buy in April 2024
7 High-Potential Penny Stocks to Buy for Massive ROI
The 3 Best Cannabis Stocks to Buy in Q2 2024
The 3 Best Meme Stocks to Buy in Q2 2024
Cronos Launches Lord Jones® Chocolate Fusions
Altria: Still Undervalued, Buy On Strength
See More Headlines
Receive CRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cronos Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Medicinals & botanicals
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
3 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$87.24 million
Book Value
$2.87 per share


Free Float
Market Cap
$943.56 million
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Michael Ryan Gorenstein J.D.Mr. Michael Ryan Gorenstein J.D. (Age 37)
    President, CEO & Chairman
    Comp: $3.94M
  • Mr. James Holm (Age 41)
    Chief Financial Officer
    Comp: $314.31k
  • Mr. Jeffrey David Jacobson (Age 38)
    Chief Growth Officer
    Comp: $730.12k
  • Ms. Anna Shlimak (Age 38)
    Senior Vice President of Corporate Affairs & Strategy
    Comp: $530.5k
  • Mr. James Andrew McGinness III (Age 45)
    VP, Controller & Principal Accounting Officer
  • Mr. Shayne J. Laidlaw
    Director of Investor Relations & Strategy
  • Mr. Terry Gregory-Joseph Doucet (Age 34)
    General Counsel & Corporate Secretary
  • Ms. Shannon Buggy (Age 54)
    Senior VP & Global Head of People
    Comp: $438.81k
  • Mr. Arye Weigensberg (Age 41)
    Senior VP & Head of Research and Development

CRON Stock Analysis - Frequently Asked Questions

Should I buy or sell Cronos Group stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cronos Group in the last twelve months. There are currently 1 sell rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CRON shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRON, but not buy additional shares or sell existing shares.
View CRON analyst ratings
or view top-rated stocks.

What is Cronos Group's stock price target for 2024?

3 brokerages have issued twelve-month target prices for Cronos Group's shares. Their CRON share price targets range from $2.50 to $3.00. On average, they predict the company's share price to reach $2.83 in the next twelve months. This suggests a possible upside of 14.7% from the stock's current price.
View analysts price targets for CRON
or view top-rated stocks among Wall Street analysts.

How have CRON shares performed in 2024?

Cronos Group's stock was trading at $2.09 at the beginning of the year. Since then, CRON shares have increased by 18.2% and is now trading at $2.47.
View the best growth stocks for 2024 here

Are investors shorting Cronos Group?

Cronos Group saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 5,550,000 shares, a drop of 13.8% from the March 15th total of 6,440,000 shares. Based on an average trading volume of 2,860,000 shares, the days-to-cover ratio is presently 1.9 days. Currently, 2.8% of the company's shares are short sold.
View Cronos Group's Short Interest

When is Cronos Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our CRON earnings forecast

How were Cronos Group's earnings last quarter?

Cronos Group Inc. (NASDAQ:CRON) announced its earnings results on Thursday, February, 29th. The company reported ($0.05) EPS for the quarter. The business earned $23.92 million during the quarter, compared to the consensus estimate of $25.15 million. Cronos Group had a negative net margin of 84.15% and a negative trailing twelve-month return on equity of 3.99%.

What other stocks do shareholders of Cronos Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cronos Group investors own include Tilray (TLRY), NVIDIA (NVDA), Advanced Micro Devices (AMD), Dollar Tree (DLTR), Micron Technology (MU), Alibaba Group (BABA) and Organigram (OGI).

Who are Cronos Group's major shareholders?

Cronos Group's stock is owned by many different retail and institutional investors. Top institutional shareholders include IMC Chicago LLC (0.00%), SeaCrest Wealth Management LLC (0.02%), Madrona Financial Services LLC (0.01%) and Revisor Wealth Management LLC (0.01%).
View institutional ownership trends

How do I buy shares of Cronos Group?

Shares of CRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRON) was last updated on 4/24/2024 by Staff

From Our Partners